An Exploratory Retrospective Comparison of Crisugabalin and Pregabalin Among 12-Week Treatment Completers With Postherpetic Neuralgia

Background

Pregabalin (PGB) is commonly used for postherpetic neuralgia (PHN), but its clinical effectiveness may be limited by insufficient pain relief or adverse events (AEs). Crisugabalin (CGB) is a novel α2δ-1 ligand that has demonstrated efficacy in randomized placebo-controlled trials. However, comparative real-world evidence for CGB and PGB remains limited.

Methods